
## Antoni Camins

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2983773/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Metal-Based Nanoparticles as Antimicrobial Agents: An Overview. Nanomaterials, 2020, 10, 292.	4.1	769
2	Dietary resveratrol prevents Alzheimer's markers and increases life span in SAMP8. Age, 2013, 35, 1851-1865.	3.0	224
3	Dual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer's disease mice model. Journal of Controlled Release, 2019, 301, 62-75.	9.9	207
4	Current Research Therapeutic Strategies for Alzheimer's Disease Treatment. Neural Plasticity, 2016, 2016, 1-15.	2.2	200
5	The sirtuin pathway in ageing and Alzheimer disease: mechanistic and therapeutic considerations. Lancet Neurology, The, 2011, 10, 275-279.	10.2	197
6	Low-dose pterostilbene, but not resveratrol, is a potent neuromodulator in aging and Alzheimer's disease. Neurobiology of Aging, 2012, 33, 2062-2071.	3.1	195
7	Novel Donepezil-Based Inhibitors of Acetyl- and Butyrylcholinesterase and Acetylcholinesterase-Induced β-Amyloid Aggregation. Journal of Medicinal Chemistry, 2008, 51, 3588-3598.	6.4	186
8	From Aging to Alzheimer's Disease: Unveiling "The Switch―with the Senescence-Accelerated Mouse Model (SAMP8). Journal of Alzheimer's Disease, 2008, 15, 615-624.	2.6	177
9	Memantine loaded PLGA PEGylated nanoparticles for Alzheimer's disease: in vitro and in vivo characterization. Journal of Nanobiotechnology, 2018, 16, 32.	9.1	163
10	Early alterations in energy metabolism in the hippocampus of APPswe/PS1dE9 mouse model of Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1556-1566.	3.8	161
11	Resveratrol and Neurodegenerative Diseases: Activation of SIRT1 as the Potential Pathway towards Neuroprotection. Current Neurovascular Research, 2009, 6, 70-81.	1.1	151
12	Memantine for the Treatment of Dementia: A Review on its Current and Future Applications. Journal of Alzheimer's Disease, 2018, 62, 1223-1240.	2.6	150
13	Current Applications of Nanoemulsions in Cancer Therapeutics. Nanomaterials, 2019, 9, 821.	4.1	147
14	Neuroprotective Role of Trans-Resveratrol in a Murine Model of Familial Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 42, 1209-1220.	2.6	141
15	Excitotoxicity in the pathogenesis of neurological and psychiatric disorders: Therapeutic implications. Journal of Psychopharmacology, 2018, 32, 265-275.	4.0	136
16	High-fat diet-induced deregulation of hippocampal insulin signaling and mitochondrial homeostasis deficiences contribute to Alzheimer disease pathology in rodents. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 1687-1699.	3.8	134
17	Hyperphosphorylation of microtubule-associated protein tau in senescence-accelerated mouse (SAM). Mechanisms of Ageing and Development, 2005, 126, 1300-1304.	4.6	127
18	Different glial response to methamphetamine- and methylenedioxymethamphetamine-induced neurotoxicity. Naunyn-Schmiedeberg's Archives of Pharmacology, 2003, 367, 490-499.	3.0	123

#	Article	IF	CITATIONS
19	Early Amyloid Accumulation in the Hippocampus of SAMP8 Mice. Journal of Alzheimer's Disease, 2010, 19, 1303-1315.	2.6	119
20	Involvement of Calpain Activation in Neurodegenerative Processes. CNS Neuroscience & Therapeutics, 2006, 12, 135-148.	4.0	117
21	Role of Cell Cycle Re-Entry in Neurons: A Common Apoptotic Mechanism of Neuronal Cell Death. Neurotoxicity Research, 2012, 22, 195-207.	2.7	117
22	Activation of nuclear factor-κB in the rat brain after transient focal ischemia. Molecular Brain Research, 1999, 65, 61-69.	2.3	116
23	Advanced Formulation Approaches for Ocular Drug Delivery: State-Of-The-Art and Recent Patents. Pharmaceutics, 2019, 11, 460.	4.5	115
24	The role of CDK5/P25 formation/inhibition in neurodegeneration. Drug News and Perspectives, 2006, 19, 453.	1.5	115
25	Protective effects of C-phycocyanin against kainic acid-induced neuronal damage in rat hippocampus. Neuroscience Letters, 1999, 276, 75-78.	2.1	111
26	PEGylated PLGA nanospheres optimized by design of experiments for ocular administration of dexibuprofen—in vitro, ex vivo and in vivo characterization. Colloids and Surfaces B: Biointerfaces, 2016, 145, 241-250.	5.0	108
27	Modulation of SIRT1 expression in different neurodegenerative models and human pathologies. Neuroscience, 2008, 154, 1388-1397.	2.3	106
28	Neurophysiological and epigenetic effects of physical exercise on the aging process. Ageing Research Reviews, 2011, 10, 475-486.	10.9	98
29	Comparative analysis of the effects of resveratrol in two apoptotic models: Inhibition of complex I and potassium deprivation in cerebellar neurons. Neuroscience, 2007, 147, 746-756.	2.3	96
30	Evaluation of potential proâ€survival pathways regulated by melatonin in a murine senescence model. Journal of Pineal Research, 2008, 45, 497-505.	7.4	94
31	Epigenetic mechanisms underlying cognitive impairment and Alzheimer disease hallmarks in 5XFAD mice. Aging, 2016, 8, 664-684.	3.1	94
32	Neurotoxicity of amphetamine derivatives is mediated by caspase pathway activation in rat cerebellar granule cells. Toxicology and Applied Pharmacology, 2004, 196, 223-234.	2.8	93
33	Antiâ€aging properties of melatonin in an in vitro murine senescence model: involvement of the sirtuin 1 pathway. Journal of Pineal Research, 2009, 47, 228-237.	7.4	92
34	Favorable effects of a prolonged treatment with melatonin on the level of oxidative damage and neurodegeneration in senescenceâ€accelerated mice. Journal of Pineal Research, 2008, 45, 302-311.	7.4	90
35	Kainic acid-induced apoptosis in cerebellar granule neurons: an attempt at cell cycle re-entry. NeuroReport, 2002, 13, 413-416.	1.2	89
36	Long-term treadmill exercise induces neuroprotective molecular changes in rat brain. Journal of Applied Physiology, 2011, 111, 1380-1390.	2.5	83

#	Article	IF	CITATIONS
37	Neurons from senescenceâ€accelerated SAMP8 mice are protected against frailty by the sirtuin 1 promoting agents melatonin and resveratrol. Journal of Pineal Research, 2012, 52, 271-281.	7.4	83
38	Apoptotic mechanisms involved in neurodegenerative diseases: Experimental and therapeutic approaches. Methods and Findings in Experimental and Clinical Pharmacology, 2008, 30, 43.	0.8	83
39	Increased permeability of blood–brain barrier on the hippocampus of a murine model of senescence. Mechanisms of Ageing and Development, 2007, 128, 522-528.	4.6	82
40	Modulation of Sirtuins: New Targets for Antiageing. Recent Patents on CNS Drug Discovery, 2008, 3, 61-69.	0.9	81
41	Long-term exposition to a high fat diet favors the appearance of β-amyloid depositions in the brain of C57BL/6J mice. A potential model of sporadic Alzheimer's disease. Mechanisms of Ageing and Development, 2017, 162, 38-45.	4.6	79
42	Memantine‣oaded PEGylated Biodegradable Nanoparticles for the Treatment of Glaucoma. Small, 2018, 14, 1701808.	10.0	77
43	Free radical production induced by methamphetamine in rat striatal synaptosomes. Toxicology and Applied Pharmacology, 2005, 204, 57-68.	2.8	75
44	Changes in oxidative stress parameters and neurodegeneration markers in the brain of the senescence-accelerated mice SAMP-8. Experimental Gerontology, 2006, 41, 360-367.	2.8	75
45	Elevated Oxidative Stress in the Brain of Senescence-accelerated Mice at 5ÂMonths of Age. Biogerontology, 2006, 7, 43-52.	3.9	73
46	Understanding the Role of Hypoxia Inducible Factor During Neurodegeneration for New Therapeutics Opportunities. Current Neuropharmacology, 2018, 16, 1484-1498.	2.9	73
47	Trafficking of Gold Nanoparticles Coated with the 8D3 Anti-Transferrin Receptor Antibody at the Mouse Blood–Brain Barrier. Molecular Pharmaceutics, 2015, 12, 4137-4145.	4.6	71
48	Kainate induces AKT, ERK and cdk5/GSK3β pathway deregulation, phosphorylates tau protein in mouse hippocampus. Neurochemistry International, 2007, 50, 435-442.	3.8	70
49	Una revisión de los avances en la terapéutica de la enfermedad de Alzheimer: estrategia frente a la proteÃna β-amiloide. NeurologÃa, 2018, 33, 47-58.	0.7	70
50	Microgliosis and down-regulation of adenosine transporter induced by methamphetamine in rats. Brain Research, 1998, 814, 120-126.	2.2	69
51	Inhibition of the cdk5/p25 fragment formation may explain the antiapoptotic effects of melatonin in an experimental model of Parkinson's disease. Journal of Pineal Research, 2006, 40, 251-258.	7.4	68
52	Cell cycle activation in striatal neurons from Huntington's disease patients and rats treated with 3â€nitropropionic acid. International Journal of Developmental Neuroscience, 2008, 26, 665-671.	1.6	68
53	Environmental Enrichment Modified Epigenetic Mechanisms in SAMP8 Mouse Hippocampus by Reducing Oxidative Stress and Inflammaging and Achieving Neuroprotection. Frontiers in Aging Neuroscience, 2016, 8, 241.	3.4	68
54	Current advances in the development of novel polymeric nanoparticles for the treatment of neurodegenerative diseases. Nanomedicine, 2020, 15, 1239-1261.	3.3	68

#	Article	IF	CITATIONS
55	Mitochondrial membrane potential measurement in rat cerebellar neurons by flow cytometry. , 1997, 28, 74-80.		67
56	Sirtuin activators: Designing molecules to extend life span. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2010, 1799, 740-749.	1.9	67
57	Alpha-Secretase ADAM10 Regulation: Insights into Alzheimer's Disease Treatment. Pharmaceuticals, 2018, 11, 12.	3.8	67
58	Molecular and Biochemical Features in Alzheimers Disease. Current Pharmaceutical Design, 2006, 12, 4389-4408.	1.9	65
59	New potential strategies for Alzheimer's disease prevention: pegylated biodegradable dexibuprofen nanospheres administration to APPswe/PS1dE9. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 1171-1182.	3.3	64
60	Masitinib for the treatment of mild to moderate Alzheimer's disease. Expert Review of Neurotherapeutics, 2015, 15, 587-596.	2.8	63
61	Environmental Enrichment Improves Behavior, Cognition, and Brain Functional Markers in Young Senescence-Accelerated Prone Mice (SAMP8). Molecular Neurobiology, 2016, 53, 2435-2450.	4.0	63
62	Neuroprotective Effects of β-Caryophyllene against Dopaminergic Neuron Injury in a Murine Model of Parkinson's Disease Induced by MPTP. Pharmaceuticals, 2017, 10, 60.	3.8	60
63	Epigallocatechin-3-gallate loaded PEGylated-PLGA nanoparticles: A new anti-seizure strategy for temporal lobe epilepsy. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 1073-1085.	3.3	60
64	Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer's disease: from current to future challenges. Journal of Nanobiotechnology, 2021, 19, 122.	9.1	60
65	Chronic administration of melatonin reduces cerebral injury biomarkers in SAMP8. Journal of Pineal Research, 2007, 42, 394-402.	7.4	58
66	Long-term physical exercise induces changes in sirtuin 1 pathway and oxidative parameters in adult rat tissues. Experimental Gerontology, 2012, 47, 925-935.	2.8	58
67	Downregulation of canonical Wnt signaling in hippocampus of SAMP8 mice. Neurobiology of Aging, 2015, 36, 720-729.	3.1	58
68	Behaviour and cognitive changes correlated with hippocampal neuroinflammaging and neuronal markers in female SAMP8, a model of accelerated senescence. Experimental Gerontology, 2016, 80, 57-69.	2.8	57
69	Potential Mechanisms Involved in the Prevention of Neurodegenerative Diseases by Lithium. CNS Neuroscience and Therapeutics, 2009, 15, 333-344.	3.9	56
70	Novel Huprine Derivatives with Inhibitory Activity toward βâ€Amyloid Aggregation and Formation as Diseaseâ€Modifying Antiâ€Alzheimer Drug Candidates. ChemMedChem, 2010, 5, 1855-1870.	3.2	56
71	Resveratrol Protects SAMP8 Brain Under Metabolic Stress: Focus on Mitochondrial Function and Wnt Pathway. Molecular Neurobiology, 2017, 54, 1661-1676.	4.0	55
72	Carbonyl stress and NMDA receptor activation contribute to methylglyoxal neurotoxicity. Free Radical Biology and Medicine, 2006, 40, 779-790.	2.9	53

#	Article	IF	CITATIONS
73	Activation of the calpain/cdk5/p25 pathway in the girus cinguli in Parkinson's disease. Parkinsonism and Related Disorders, 2008, 14, 309-313.	2.2	53
74	Evidence in favour of a role for peripheral-type benzodiazepine receptor ligands in amplification of neuronal apoptosis. Apoptosis: an International Journal on Programmed Cell Death, 2005, 10, 91-104.	4.9	52
75	The antiproliferative activity of melatonin in B65 rat dopaminergic neuroblastoma cells is related to the downregulation of cell cycleâ€related genes. Journal of Pineal Research, 2008, 45, 8-16.	7.4	52
76	Melatonin alters cell death processes in response to ageâ€related oxidative stress in the brain of senescenceâ€accelerated mice. Journal of Pineal Research, 2009, 46, 106-114.	7.4	52
77	Wnt pathway regulation by long-term moderate exercise in rat hippocampus. Brain Research, 2014, 1543, 38-48.	2.2	52
78	ADAM10 in Alzheimer's disease: Pharmacological modulation by natural compounds and its role as a peripheral marker. Biomedicine and Pharmacotherapy, 2019, 113, 108661.	5.6	52
79	Epigallocatechin-3-Gallate (EGCG) Improves Cognitive Deficits Aggravated by an Obesogenic Diet Through Modulation of Unfolded Protein Response in APPswe/PS1dE9 Mice. Molecular Neurobiology, 2020, 57, 1814-1827.	4.0	51
80	C-Phycocyanin protects cerebellar granule cells from low potassium/serum deprivation-induced apoptosis. Naunyn-Schmiedeberg's Archives of Pharmacology, 2001, 364, 96-104.	3.0	50
81	Dysfunction of astrocytes in senescenceâ€accelerated mice SAMP8 reduces their neuroprotective capacity. Aging Cell, 2008, 7, 630-640.	6.7	50
82	Lithium Treatment Decreases Activities of Tau Kinases in a Murine Model of Senescence. Journal of Neuropathology and Experimental Neurology, 2008, 67, 612-623.	1.7	49
83	Neuroprotective and anti-ageing role of leptin. Journal of Molecular Endocrinology, 2012, 49, R149-R156.	2.5	49
84	Prevention of epilepsy by taurine treatments in mice experimental model. Journal of Neuroscience Research, 2009, 87, 1500-1508.	2.9	48
85	Characterization of Amyloid-β Granules in the Hippocampus of SAMP8 Mice. Journal of Alzheimer's Disease, 2011, 25, 535-546.	2.6	48
86	Antiapoptotic Drugs: A Therapautic Strategy for the Prevention of Neurodegenerative Diseases. Current Pharmaceutical Design, 2011, 17, 230-245.	1.9	48
87	Dendritic Spine Abnormalities in Hippocampal CA1 Pyramidal Neurons Underlying Memory Deficits in the SAMP8 Mouse Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 32, 233-240.	2.6	47
88	Evaluation of Neuropathological Effects of a High-Fat Diet in a Presymptomatic Alzheimer's Disease Stage in APP/PS1 Mice. Journal of Alzheimer's Disease, 2016, 54, 233-251.	2.6	46
89	Review of the advances in treatment for Alzheimer disease: strategies for combating β-amyloid protein. NeurologÃa (English Edition), 2018, 33, 47-58.	0.4	46
90	Inhibition of Cell Cycle Pathway by Flavopiridol Promotes Survival of Cerebellar Granule Cells after an Excitotoxic Treatment. Journal of Pharmacology and Experimental Therapeutics, 2004, 308, 609-616.	2.5	45

#	Article	IF	CITATIONS
91	The Implication of the Brain Insulin Receptor in Late Onset Alzheimer's Disease Dementia. Pharmaceuticals, 2018, 11, 11.	3.8	45
92	Discovery of a Potent Dual Inhibitor of Acetylcholinesterase and Butyrylcholinesterase with Antioxidant Activity that Alleviates Alzheimer-like Pathology in Old APP/PS1 Mice. Journal of Medicinal Chemistry, 2021, 64, 812-839.	6.4	45
93	Inhibition of cyclin-dependent kinases is neuroprotective in 1-methyl-4-phenylpyridinium-induced apoptosis in neurons. Neuroscience, 2007, 146, 350-365.	2.3	44
94	Metabolic Stress Induces Cognitive Disturbances and Inflammation in Aged Mice: Protective Role of Resveratrol. Rejuvenation Research, 2017, 20, 202-217.	1.8	44
95	Dexibuprofen Biodegradable Nanoparticles: One Step Closer towards a Better Ocular Interaction Study. Nanomaterials, 2020, 10, 720.	4.1	44
96	Kainic acid-induced neuronal cell death in cerebellar granule cells is not prevented by caspase inhibitors. British Journal of Pharmacology, 2002, 135, 1297-1307.	5.4	43
97	A new method for determining blood–brain barrier integrity based on intracardiac perfusion of an Evans Blue–Hoechst cocktail. Journal of Neuroscience Methods, 2008, 174, 42-49.	2.5	43
98	Activation of Akt by lithium: Pro-survival pathways in aging. Mechanisms of Ageing and Development, 2009, 130, 253-261.	4.6	43
99	Neuronal in vitro models for the estimation of acute systemic toxicity. Toxicology in Vitro, 2009, 23, 1564-1569.	2.4	42
100	Neuroprotective role of intermittent fasting in senescence-accelerated mice P8 (SAMP8). Experimental Gerontology, 2010, 45, 702-710.	2.8	42
101	Long-Term Exercise Modulates Hippocampal Gene Expression in Senescent Female Mice. Journal of Alzheimer's Disease, 2013, 33, 1177-1190.	2.6	42
102	Oxidative stress-induced DNA damage and cell cycle regulation in B65 dopaminergic cell line. Free Radical Research, 2009, 43, 985-994.	3.3	41
103	An evaluation of the neuroprotective effects of melatonin in an in vitro experimental model of ageâ€induced neuronal apoptosis. Journal of Pineal Research, 2009, 46, 262-267.	7.4	41
104	Role of matrix metalloproteinaseâ€9 (MMPâ€9) in striatal blood–brain barrier disruption in a 3â€nitropropionic acid model of Huntington's disease. Neuropathology and Applied Neurobiology, 2011, 37, 525-537.	3.2	41
105	Cerebral Amyloid Angiopathy, Blood-Brain Barrier Disruption and Amyloid Accumulation in SAMP8 Mice. Neurodegenerative Diseases, 2011, 8, 421-429.	1.4	41
106	Determination of nitric oxide generation in mammalian neurons using dichlorofluorescin diacetate and flow cytometry. Journal of Pharmacological and Toxicological Methods, 1997, 38, 93-98.	0.7	40
107	Orphenadrine prevents 3-nitropropionic acid-induced neurotoxicity in vitro and in vivo. British Journal of Pharmacology, 2001, 132, 693-702.	5.4	40
108	Implication of the transcription factor E2F-1 in the modulation of neuronal apoptosis. Biomedicine and Pharmacotherapy, 2007, 61, 390-399.	5.6	40

#	Article	IF	CITATIONS
109	Evaluation of hypoxia inducible factor expression in inflammatory and neurodegenerative brain models. International Journal of Biochemistry and Cell Biology, 2013, 45, 1377-1388.	2.8	40
110	The Involvement of Peripheral and Brain Insulin Resistance in Late Onset Alzheimer's Dementia. Frontiers in Aging Neuroscience, 2019, 11, 236.	3.4	40
111	Neuroprotective action of flavopiridol, a cyclin-dependent kinase inhibitor, in colchicine-induced apoptosis. Neuropharmacology, 2003, 45, 672-683.	4.1	39
112	Timeâ€course of blood–brain barrier disruption in senescenceâ€accelerated mouse prone 8 (SAMP8) mice. International Journal of Developmental Neuroscience, 2009, 27, 47-52.	1.6	38
113	State-of-the-art polymeric nanoparticles as promising therapeutic tools against human bacterial infections. Journal of Nanobiotechnology, 2020, 18, 156.	9.1	38
114	A flow cytometric study ofN-methyl-d-aspartate effects on dissociated cerebellar cells. Brain Research, 1996, 723, 110-114.	2.2	37
115	Implication of cyclin-dependent kinase 5 in the neuroprotective properties of lithium. Neuroscience, 2005, 134, 1001-1011.	2.3	37
116	The effect of mGluR2 activation on signal transduction pathways and neuronal cell survival. Brain Research, 2009, 1249, 244-250.	2.2	37
117	Tau hyperphosphorylation and increased BACE1 and RAGE levels in the cortex of PPARβ/δ-null mice. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 1241-1248.	3.8	37
118	Age-related expression of adenosine receptors in brain from the senescence-accelerated mouse. Experimental Gerontology, 2009, 44, 453-461.	2.8	36
119	Evidence of calpain/cdk5 pathway inhibition by lithium in 3-nitropropionic acid toxicity in vivo and in vitro. Neuropharmacology, 2009, 56, 422-428.	4.1	36
120	Resveratrol Inhibits Proliferation and Promotes Apoptosis of Neuroblastoma Cells: Role of Sirtuin 1. Neurochemical Research, 2011, 36, 187-194.	3.3	36
121	Amyloid and tau pathology of familial Alzheimer's disease APP/PS1 mouse model in a senescence phenotype background (SAMP8). Age, 2015, 37, 9747.	3.0	36
122	Dexibuprofen prevents neurodegeneration and cognitive decline in APPswe/PS1dE9 through multiple signaling pathways. Redox Biology, 2017, 13, 345-352.	9.0	36
123	Study of the transcytosis of an anti-transferrin receptor antibody with a Fab′ cargo across the blood–brain barrier in mice. European Journal of Pharmaceutical Sciences, 2013, 49, 556-564.	4.0	35
124	Glutamate Excitotoxicity Activates the MAPK/ERK Signaling Pathway and Induces the Survival of Rat Hippocampal Neurons In Vivo. Journal of Molecular Neuroscience, 2014, 52, 366-377.	2.3	35
125	Benzodiazepines and Related Drugs as a Risk Factor in Alzheimer's Disease Dementia. Frontiers in Aging Neuroscience, 2019, 11, 344.	3.4	35
126	Experimental Models for Aging and their Potential for Novel Drug Discovery. Current Neuropharmacology, 2018, 16, 1466-1483.	2.9	35

#	Article	IF	CITATIONS
127	The role of leptin in the sporadic form of Alzheimer's disease. Interactions with the adipokines amylin, ghrelin and the pituitary hormone prolactin. Life Sciences, 2015, 140, 19-28.	4.3	34
128	Antiapoptotic effects of roscovitine in cerebellar granule cells deprived of serum and potassium: a cell cycle-related mechanism. Neurochemistry International, 2004, 44, 251-261.	3.8	33
129	Neuroprotective effects of caffeine against complex I inhibition–induced apoptosis are mediated by inhibition of the Atm/p53/E2Fâ€1 path in cerebellar granule neurons. Journal of Neuroscience Research, 2007, 85, 3079-3088.	2.9	33
130	Synthesis and pharmacological evaluation of several ring-contracted amantadine analogs. Bioorganic and Medicinal Chemistry, 2008, 16, 9925-9936.	3.0	33
131	Carnosine prevents methamphetamine-induced gliosis but not dopamine terminal loss in rats. European Journal of Pharmacology, 2002, 448, 165-168.	3.5	32
132	PGC-1ss Down-Regulation Is Associated With Reduced ERRÂ Activity and MCAD Expression in Skeletal Muscle of Senescence-Accelerated Mice. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2006, 61, 773-780.	3.6	32
133	Glycogen synthase kinase-3 is involved in the regulation of the cell cycle in cerebellar granule cells. Neuropharmacology, 2007, 53, 295-307.	4.1	32
134	Calpains as a Target for Therapy of Neurodegenerative Diseases: Putative Role of Lithium. Current Drug Metabolism, 2009, 10, 433-447.	1.2	32
135	Effects of Nutrition on Cognitive Function in Adults with or without Cognitive Impairment: A Systematic Review of Randomized Controlled Clinical Trials. Nutrients, 2021, 13, 3728.	4.1	32
136	A new aspect of the antiproliferative action of peripheral-type benzodiazepine receptor ligands. European Journal of Pharmacology, 1995, 272, 289-292.	3.5	31
137	Mavoglurant as a treatment for Parkinson's disease. Expert Opinion on Investigational Drugs, 2014, 23, 1165-1179.	4.1	31
138	Vulnerability of calbindin, calretinin and parvalbumin in a transgenic/knock-in APPswe/PS1dE9 mouse model of Alzheimer disease together with disruption of hippocampal neurogenesis. Experimental Gerontology, 2015, 69, 176-188.	2.8	31
139	Neuroprotection by c-Jun NH2-terminal kinase inhibitor SP600125 against potassium deprivation–induced apoptosis involves the Akt pathway and inhibition of cell cycle reentry. Neuroscience, 2009, 159, 1135-1147.	2.3	30
140	Physiological and behavioural consequences of long-term moderate treadmill exercise. Psychoneuroendocrinology, 2012, 37, 1745-1754.	2.7	30
141	PI3 k/akt inhibition induces apoptosis through p38 activation in neurons. Pharmacological Research, 2013, 70, 116-125.	7.1	29
142	Differences in activation of ERK1/2 and p38 kinase in <i>Jnk3</i> null mice following KA treatment. Journal of Neurochemistry, 2010, 114, 1315-1322.	3.9	28
143	Resveratrol induces nuclear factor-l̂®B activity in human cardiac cells. International Journal of Cardiology, 2013, 167, 2507-2516.	1.7	28
144	P38 MAPK Inhibition Protects Against Glutamate Neurotoxicity and Modifies NMDA and AMPA Receptor Subunit Expression. Journal of Molecular Neuroscience, 2015, 55, 596-608.	2.3	28

#	Article	IF	CITATIONS
145	JNK1 inhibition by Licochalcone A leads to neuronal protection against excitotoxic insults derived of kainic acid. Neuropharmacology, 2018, 131, 440-452.	4.1	28
146	Lipid Nanoparticles for the Posterior Eye Segment. Pharmaceutics, 2022, 14, 90.	4.5	28
147	Neuronal Cell Cycle Re-Entry Markers are Altered in the Senescence Accelerated Mouse P8 (SAMP8). Journal of Alzheimer's Disease, 2012, 30, 573-583.	2.6	27
148	Peroxisome Proliferator-Activated Receptor  Down-Regulation Is Associated With Enhanced Ceramide Levels in Age-Associated Cardiac Hypertrophy. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2007, 62, 1326-1336.	3.6	26
149	Surface Functionalization of PLGA Nanoparticles to Increase Transport across the BBB for Alzheimer's Disease. Applied Sciences (Switzerland), 2021, 11, 4305.	2.5	26
150	Targeting brain Renin-Angiotensin System for the prevention and treatment of Alzheimer's disease: Past, present and future. Ageing Research Reviews, 2022, 77, 101612.	10.9	26
151	Evaluation of free radical production, mitochondrial membrane potential and cytoplasmic calcium in mammalian neurons by flow cytometry. Brain Research Protocols, 1999, 4, 280-287.	1.6	25
152	Inhibition of the cdk5/MEF2 pathway is involved in the antiapoptotic properties of calpain inhibitors in cerebellar neurons. British Journal of Pharmacology, 2005, 145, 1103-1111.	5.4	25
153	Lithium prevents colchicine-induced apoptosis in rat cerebellar granule neurons. Bipolar Disorders, 2004, 6, 144-149.	1.9	24
154	Resveratrol: An Antiaging Drug with Potential Therapeutic Applications in Treating Diseases. Pharmaceuticals, 2009, 2, 194-205.	3.8	24
155	Microarray analysis of rat hippocampus exposed to excitotoxicity: Reversal Na <sup>+</sup> /Ca <sup>2+</sup> exchanger NCX3 is overexpressed in glial cells. Hippocampus, 2012, 22, 128-140.	1.9	24
156	Melatonin suppresses nitric oxide production in glial cultures by pro-inflammatory cytokines through p38 MAPK inhibition. Free Radical Research, 2014, 48, 119-128.	3.3	24
157	Obesity and neuroinflammatory phenotype in mice lacking endothelial megalin. Journal of Neuroinflammation, 2017, 14, 26.	7.2	24
158	Peripheral and Central Effects of Memantine in a Mixed Preclinical Mice Model of Obesity and Familial Alzheimer's Disease. Molecular Neurobiology, 2018, 55, 7327-7339.	4.0	24
159	Retinoblastoma protein phosphorylation at multiple sites is associated with neurofibrillary pathology in Alzheimer disease. International Journal of Clinical and Experimental Pathology, 2008, 1, 134-46.	0.5	24
160	Neuroprotective effects of (±)-huprine Y on in vitro and in vivo models of excitoxicity damage. Experimental Neurology, 2003, 180, 123-130.	4.1	23
161	Inhibition of Ataxia Telangiectasia-p53-E2F-1 Pathway in Neurons as a Target for the Prevention of Neuronal Apoptosis. Current Drug Metabolism, 2007, 8, 709-715.	1.2	23
162	Content and traffic of taurine in hippocampal reactive astrocytes. Hippocampus, 2011, 21, 185-197.	1.9	23

#	Article	IF	CITATIONS
163	Resveratrol modulates response against acute inflammatory stimuli in aged mouse brain. Experimental Gerontology, 2018, 102, 3-11.	2.8	23
164	3-Nitropropionic acid activates calpain/cdk5 pathway in rat striatum. Neuroscience Letters, 2007, 421, 77-81.	2.1	22
165	Blood-brain barrier disruption in the striatum of rats treated with 3-nitropropionic acid. NeuroToxicology, 2009, 30, 136-143.	3.0	22
166	Amyloid-β impairs mitochondrial dynamics and autophagy in Alzheimer's disease experimental models. Scientific Reports, 2022, 12, .	3.3	22
167	A molecular study of pathways involved in the inhibition of cell proliferation in neuroblastoma B65 cells by the GSKâ€3 inhibitors lithium and SBâ€415286. Journal of Cellular and Molecular Medicine, 2009, 13, 3906-3917.	3.6	21
168	Evaluation of pathways involved in pentachlorophenol-induced apoptosis in rat neurons. NeuroToxicology, 2009, 30, 451-458.	3.0	21
169	Activation of ataxia telangiectasia muted under experimental models and human Parkinson's disease. Cellular and Molecular Life Sciences, 2010, 67, 3865-3882.	5.4	21
170	An overview of investigational antiapoptotic drugs with potential application for the treatment of neurodegenerative disorders. Expert Opinion on Investigational Drugs, 2010, 19, 587-604.	4.1	21
171	Presence of a neo-epitope and absence of amyloid beta and tau protein in degenerative hippocampal granules of aged mice. Age, 2014, 36, 151-165.	3.0	21
172	Early Preclinical Changes in Hippocampal CREB-Binding Protein Expression in a Mouse Model of Familial Alzheimer's Disease. Molecular Neurobiology, 2018, 55, 4885-4895.	4.0	21
173	Modulation of neuronal mitochondrial membrane potential by the NMDA receptor: role of arachidonic acid. Brain Research, 1997, 777, 69-74.	2.2	20
174	HIF-1α expression in the hippocampus and peripheral macrophages after glutamate-induced excitotoxicity. Journal of Neuroimmunology, 2011, 238, 12-18.	2.3	20
175	Aging biology: a new frontier for drug discovery. Expert Opinion on Drug Discovery, 2012, 7, 217-229.	5.0	20
176	Neuroprotective Effects of the Absence of JNK1 or JNK3 Isoforms on Kainic Acid-Induced Temporal Lobe Epilepsy-Like Symptoms. Molecular Neurobiology, 2018, 55, 4437-4452.	4.0	20
177	JNK Isoforms Are Involved in the Control of Adult Hippocampal Neurogenesis in Mice, Both in Physiological Conditions and in an Experimental Model of Temporal Lobe Epilepsy. Molecular Neurobiology, 2019, 56, 5856-5865.	4.0	20
178	Cell surface expression of heat shock proteins in dog neutrophils induced by mitochondrial benzodiazepine receptor ligands. Immunopharmacology, 1995, 29, 159-166.	2.0	19
179	3-amino thioacridone, a selective cyclin-dependent kinase 4 inhibitor, attenuates kainic acid-induced apoptosis in neurons. Neuroscience, 2003, 120, 599-603.	2.3	19
180	Neuroprotective effects of SBâ€415286 on hydrogen peroxideâ€induced cell death in B65 rat neuroblastoma cells and neurons. International Journal of Developmental Neuroscience, 2008, 26, 269-276.	1.6	19

#	Article	IF	CITATIONS
181	New oxapolycyclic cage amines with NMDA receptor antagonist and trypanocidal activities. Bioorganic and Medicinal Chemistry, 2010, 18, 46-57.	3.0	19
182	MDMA enhances hippocampal-dependent learning and memory under restrictive conditions, and modifies hippocampal spine density. Psychopharmacology, 2014, 231, 863-874.	3.1	19
183	Hypercholesterolemia and neurodegeneration. Comparison of hippocampal phenotypes in LDLr knockout and APPswe/PS1dE9 mice. Experimental Gerontology, 2015, 65, 69-78.	2.8	19
184	Adipokine pathways are altered in hippocampus of an experimental mouse model of Alzheimer's disease. Journal of Nutrition, Health and Aging, 2015, 19, 403-412.	3.3	19
185	Evaluation of the Role of JNK1 in the Hippocampus in an Experimental Model of Familial Alzheimer's Disease. Molecular Neurobiology, 2016, 53, 6183-6193.	4.0	19
186	Role of JNK isoforms in the kainic acid experimental model of epilepsy and neurodegeneration. Frontiers in Bioscience - Landmark, 2017, 22, 795-814.	3.0	19
187	A metabolic perspective of late onset Alzheimer's disease. Pharmacological Research, 2019, 145, 104255.	7.1	19
188	Metformin a Potential Pharmacological Strategy in Late Onset Alzheimer's Disease Treatment. Pharmaceuticals, 2021, 14, 890.	3.8	19
189	Systemic administration of 3-nitropropionic acid points out a different role for active caspase-3 in neurons and astrocytes. Neurochemistry International, 2010, 56, 443-450.	3.8	18
190	Role of c-Jun N-Terminal Kinases (JNKs) in Epilepsy and Metabolic Cognitive Impairment. International Journal of Molecular Sciences, 2020, 21, 255.	4.1	18
191	Epigallocatechin-3-gallate PEGylated poly(lactic-co-glycolic) acidÂnanoparticles mitigate striatal pathology and motor deficits in 3-nitropropionic acid intoxicated mice. Nanomedicine, 2021, 16, 19-35.	3.3	18
192	Evaluation of the neuronal apoptotic pathways involved in cytoskeletal disruption-induced apoptosis. Biochemical Pharmacology, 2005, 70, 470-480.	4.4	17
193	Flavopiridol: an antitumor drug with potential application in the treatment of neurodegenerative diseases. Medical Hypotheses, 2005, 64, 120-123.	1.5	17
194	Taurine treatment inhibits CaMKII activity and modulates the presence of calbindin D28k, calretinin, and parvalbumin in the brain. Journal of Neuroscience Research, 2010, 88, 136-142.	2.9	17
195	The therapeutic potential of metabolic hormones in the treatment of age-related cognitive decline and Alzheimer's disease. Nutrition Research, 2016, 36, 1305-1315.	2.9	17
196	Further characterization of an adenosine transport system in the mitochondrial fraction of rat testis. European Journal of Pharmacology, 2000, 398, 31-39.	3.5	16
197	MPP+ Injection into Rat Substantia Nigra Causes Secondary Glial Activation but Not Cell Death in the Ipsilateral Striatum. Neurobiology of Disease, 2000, 7, 343-361.	4.4	16
198	Adaptive Plasticity in the Hippocampus of Young Mice Intermittently Exposed to MDMA Could Be the Origin of Memory Deficits. Molecular Neurobiology, 2016, 53, 7271-7283.	4.0	16

#	Article	IF	CITATIONS
199	Effect of glutamate receptor ligands on mitochondrial membrane potential in rat dissociated cerebellar cells. Naunyn-Schmiedeberg's Archives of Pharmacology, 1996, 354, 420-423.	3.0	15
200	Different capacities of various NMDA receptor antagonists to prevent ischemia-induced neurodegeneration in human cultured NT2 neurons. Neurochemistry International, 2006, 49, 466-474.	3.8	15
201	The p38MAPK signaling pathway regulates neuronal apoptosis through the phosphorylation of the retinoblastoma protein. Neurochemistry International, 2009, 54, 99-105.	3.8	15
202	Evaluation of transcriptional activity of caspase-3 gene as a marker of acute neurotoxicity in rat cerebellar granular cells. Toxicology in Vitro, 2010, 24, 465-471.	2.4	15
203	GSK3β inhibition is involved in the neuroprotective effects of cyclin-dependent kinase inhibitors in neurons. Pharmacological Research, 2012, 65, 66-73.	7.1	15
204	Anti-inflammatory role of Leptin in glial cells through p38 MAPK pathway inhibition. Pharmacological Reports, 2017, 69, 409-418.	3.3	15
205	Neuroprotective Effects of the Amylin Analog, Pramlintide, on Alzheimer's Disease Are Associated with Oxidative Stress Regulation Mechanisms. Journal of Alzheimer's Disease, 2019, 69, 157-168.	2.6	15
206	Development and optimization of Riluzole-loaded biodegradable nanoparticles incorporated in a mucoadhesive in situ gel for the posterior eye segment. International Journal of Pharmaceutics, 2022, 612, 121379.	5.2	15
207	Development of Peptide Targeted PLGA-PEGylated Nanoparticles Loading Licochalcone-A for Ocular Inflammation. Pharmaceutics, 2022, 14, 285.	4.5	15
208	Prosurvival role of JAK/STAT and Akt signaling pathways in MPP+-induced apoptosis in neurons. Neurochemistry International, 2010, 57, 774-782.	3.8	14
209	Gene expression profile in JNK3 null mice: a novel specific activation of the PI3K/AKT pathway. Journal of Neurochemistry, 2011, 117, 244-252.	3.9	14
210	Depression-like behavior is dependent on age in male SAMP8 mice. Biogerontology, 2013, 14, 165-176.	3.9	14
211	Masitinib for the treatment of Alzheimer's disease. Neurodegenerative Disease Management, 2021, 11, 263-276.	2.2	14
212	Metabolic Basis of Sporadic Alzeimer's Disease. Role of Hormones Related to Energy Metabolism. Current Pharmaceutical Design, 2013, 19, 6739-6748.	1.9	14
213	Biodegradable nanoparticles for the treatment of epilepsy: From current advances to future challenges. Epilepsia Open, 2022, 7, .	2.4	14
214	In vitro and in vivo protective effect of orphenadrine on glutamate neurotoxicity. Neuropharmacology, 1999, 38, 671-677.	4.1	13
215	Pharmacological Strategies to Improve Dendritic Spines in Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 82, S91-S107.	2.6	13
216	U-83836E prevents kainic acid-induced neuronal damage. Naunyn-Schmiedeberg's Archives of Pharmacology, 1998, 357, 413-418.	3.0	12

#	Article	IF	CITATIONS
217	Neuroprotection associated with alternative splicing of NMDA receptors in rat cortical neurons. British Journal of Pharmacology, 2006, 147, 622-633.	5.4	12
218	Evaluation of acute antiapoptotic effects of Li+ in neuronal cell cultures. Journal of Neural Transmission, 2007, 114, 405-416.	2.8	12
219	GSK-3β inhibition and prevention of mitochondrial apoptosis inducing factor release are not involved in the antioxidant properties of SB-415286. European Journal of Pharmacology, 2008, 588, 239-243.	3.5	12
220	Kainateâ€induced toxicity in the hippocampus: potential role of lithium. Bipolar Disorders, 2010, 12, 425-436.	1.9	12
221	Study of the pathways involved in apoptosis induced by PI3K inhibition in cerebellar granule neurons. Neurochemistry International, 2011, 59, 159-167.	3.8	12
222	KB-R7943 reduces 4-aminopyridine-induced epileptiform activity in adult rats after neuronal damage induced by neonatal monosodium glutamate treatment. Journal of Biomedical Science, 2017, 24, 27.	7.0	12
223	Receptor to Glutamate NMDA-Type: The Functional Diversity of the NR1 Isoforms and Pharmacological Properties. Current Pharmaceutical Design, 2013, 19, 6709-6719.	1.9	12
224	A Chronological Review of Potential Disease-Modifying Therapeutic Strategies for Alzheimer's Disease. Current Pharmaceutical Design, 2020, 26, 1286-1299.	1.9	12
225	Specific binding sites for [3H]Ro 5-4864 in rat prostate and seminal vesicle. General Pharmacology, 1992, 23, 381-384.	0.7	11
226	Characterization of [3H]nisoxetine binding in rat vas deferens membranes: Modulation by sigma and PCP ligands. Life Sciences, 1998, 62, 763-773.	4.3	11
227	Inhibition of Multiple Pathways Accounts for the Antiapoptotic Effects of Flavopiridol on Potassium Withdrawal-Induced Apoptosis in Neurons. Journal of Molecular Neuroscience, 2005, 26, 071-084.	2.3	11
228	Hypertriglyceridemia and Hepatic Steatosis in Senescence-Accelerated Mouse Associate to Changes in Lipid-Related Gene Expression. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2007, 62, 1219-1227.	3.6	11
229	DNA low-density array analysis of colchicine neurotoxicity in rat cerebellar granular neurons. NeuroToxicology, 2008, 29, 309-317.	3.0	11
230	Antiapoptotic effects of roscovitine on camptothecin-induced DNA damage in neuroblastoma cells. Apoptosis: an International Journal on Programmed Cell Death, 2011, 16, 536-550.	4.9	11
231	State of the Art on Toxicological Mechanisms of Metal and Metal Oxide Nanoparticles and Strategies to Reduce Toxicological Risks. Toxics, 2021, 9, 195.	3.7	11
232	Characterization of [3H]Ro 5-4864 Binding Sites in Rat Vas Deferens. Journal of Neurochemistry, 1992, 58, 39-45.	3.9	10
233	Inhibition of CDKs: A Strategy for Preventing Kainic Acid-Induced Apoptosis in Neurons. Annals of the New York Academy of Sciences, 2003, 1010, 671-674.	3.8	10
234	Regulation of GSKâ€3β by calpain in the 3â€nitropropionic acid model. Hippocampus, 2010, 20, 962-970.	1.9	10

#	Article	IF	CITATIONS
235	ATM is involved in cellâ $\in$ cycle control through the regulation of retinoblastoma protein phosphorylation. Journal of Cellular Biochemistry, 2010, 110, 210-218.	2.6	10
236	Effects of MPP+ on the molecular pathways involved in cell cycle control in B65 neuroblastoma cells. Pharmacological Research, 2010, 61, 391-399.	7.1	10
237	Clustered granules present in the hippocampus of aged mice result from a degenerative process affecting astrocytes and their surrounding neuropil. Age, 2014, 36, 9690.	3.0	10
238	A Single Dose of Pirfenidone Attenuates Neuronal Loss and Reduces Lipid Peroxidation after Kainic Acid-Induced Excitotoxicity in the Pubescent Rat Hippocampus. Journal of Molecular Neuroscience, 2014, 52, 193-201.	2.3	10
239	The Ethyl Acetate Extract of Leaves of Ugni molinae Turcz. Improves Neuropathological Hallmarks of Alzheimer's Disease in Female APPswe/PS1dE9 Mice Fed with a High Fat Diet. Journal of Alzheimer's Disease, 2018, 66, 1175-1191.	2.6	10
240	c-Jun N-terminal Kinase 1 ablation protects against metabolic-induced hippocampal cognitive impairments. Journal of Molecular Medicine, 2019, 97, 1723-1733.	3.9	10
241	Characterization and differentiation of peripheral-type benzodiazepine receptors in rat and human prostate. Life Sciences, 1994, 54, 759-767.	4.3	9
242	Characterization of nitrobenzylthioinosine binding sites in the mitochondrial fraction of rat testis. Life Sciences, 1996, 58, 753-759.	4.3	9
243	Lack of Junâ€Nâ€ŧerminal kinase 3 (JNK3) does not protect against neurodegeneration induced by 3â€nitropropionic acid. Neuropathology and Applied Neurobiology, 2012, 38, 311-321.	3.2	9
244	3,4-Methylenedioxymethamphetamine enhances kainic acid convulsive susceptibility. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 54, 231-242.	4.8	9
245	Mice Lacking Functional Fas Death Receptors Are Protected from Kainic Acid-Induced Apoptosis in the Hippocampus. Molecular Neurobiology, 2015, 52, 120-129.	4.0	9
246	Synthesis and Calcium Channel Blocking Activity of 4-Indolyl-1,4-dihydropyridines. Bioorganic Chemistry, 1997, 25, 169-178.	4.1	8
247	Cell-surface Expression of Heat Shock proteins in Dog Neutrophils after Oxidative Stress. Toxicology in Vitro, 1999, 13, 437-443.	2.4	8
248	Evaluation of neuronal cell death by laser scanning cytometry. Brain Research Protocols, 2002, 9, 41-48.	1.6	8
249	Pirfenidone Attenuates Microglial Reactivity and Reduces Inducible Nitric Oxide Synthase mRNA Expression After Kainic Acid-Mediated Excitotoxicity in Pubescent Rat Hippocampus. Journal of Molecular Neuroscience, 2015, 56, 245-254.	2.3	8
250	Involvement of JNK1 in Neuronal Polarization During Brain Development. Cells, 2020, 9, 1897.	4.1	8
251	Endothelial-specific deficiency of megalin in the brain protects mice against high-fat diet challenge. Journal of Neuroinflammation, 2020, 17, 22.	7.2	8
252	Reactive Oxygen Production by Glutamate Agonists in Dissociated Cerebellar Cells: A Flow Cytometric Study. General Pharmacology, 1998, 30, 507-511.	0.7	7

#	Article	IF	CITATIONS
253	Cyclosporin A enhances colchicine-induced apoptosis in rat cerebellar granule neurons. British Journal of Pharmacology, 2004, 141, 661-669.	5.4	7
254	Synthesis, uptake and release of taurine in astrocytes treated with 8-Br-cAMP. Neuroscience Letters, 2009, 467, 199-202.	2.1	7
255	Effects of MDMA on neuroplasticity, amyloid burden and phospho-tau expression in APPswe/PS1dE9 mice. Journal of Psychopharmacology, 2019, 33, 1170-1182.	4.0	7
256	c-Jun N-Terminal Kinases in Alzheimer's Disease: A Possible Target for the Modulation of the Earliest Alterations. Journal of Alzheimer's Disease, 2021, 82, S127-S139.	2.6	7
257	Dexibuprofen ameliorates peripheral and central risk factors associated with Alzheimer's disease in metabolically stressed APPswe/PS1dE9 mice. Cell and Bioscience, 2021, 11, 141.	4.8	7
258	Novel Insights into the Molecular Mechanisms Involved in the Neuroprotective Effects of C-Phycocyanin against Brain Ischemia in Rats. Current Pharmaceutical Design, 2022, 28, 1187-1197.	1.9	7
259	Effect of PCP and sigma ligands on both noradrenaline- and electrically-induced contractions and on [3H]-noradrenaline uptake in rat vas deferens. Autonomic and Autacoid Pharmacology, 1998, 18, 239-244.	0.6	6
260	Neuronal apoptosis in the striatum of rats treated with 3-nitropropionic acid is not triggered by cell-cycle re-entry. NeuroToxicology, 2011, 32, 734-741.	3.0	6
261	Adolescent exposure to MDMA induces dopaminergic toxicity in substantia nigra and potentiates the amyloid plaque deposition in the striatum of APPswe/PS1dE9 mice. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 1815-1826.	3.8	6
262	Role of brain câ€Jun Nâ€ŧerminal kinase 2 in the control of the insulin receptor and its relationship with cognitive performance in a highâ€fat diet preâ€clinical model. Journal of Neurochemistry, 2019, 149, 255-268.	3.9	6
263	Effects of U-83836E on Glutamate-Induced Neurotoxicity in Dissociated Rat Cerebellar Granule Cells. Toxicology and Applied Pharmacology, 1999, 156, 1-5.	2.8	5
264	[6] Flow cytometric determination of cytoplasmic oxidants and mitochondrial membrane potential in neuronal cells. Methods in Enzymology, 2002, 352, 71-79.	1.0	5
265	Assessment of the Adrenergic Effects of Orphenadrine in Rat Vas Deferens. Journal of Pharmacy and Pharmacology, 2010, 51, 307-312.	2.4	5
266	Expression pattern of ataxia telangiectasia mutated (ATM), p53, Akt, and glycogen synthase kinaseâ€3β in the striatum of rats treated with 3â€nitropropionic acid. Journal of Neuroscience Research, 2012, 90, 1803-1813.	2.9	5
267	Triple GLP-1/GIP/glucagon receptor agonists, a potential novel treatment strategy in Alzheimer's disease. Expert Opinion on Investigational Drugs, 2019, 28, 93-97.	4.1	5
268	The preclinical discovery and development of opicapone for the treatment of Parkinson's disease. Expert Opinion on Drug Discovery, 2020, 15, 993-1003.	5.0	5
269	Inhibitors of Cyclin-Dependent Kinases: Potential Drugs for the Treatment of Neurodegenerative Disorders?. Current Medicinal Chemistry - Central Nervous System Agents, 2005, 5, 101-109.	0.5	3
270	Hepatic Gene Expression Changes in an Experimental Model of Accelerated Senescence: The SAM-P8 Mouse. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2008, 63, 1043-1052.	3.6	3

#	Article	IF	CITATIONS
271	Aging control with resveratrol. Drug Discovery Today: Therapeutic Strategies, 2010, 7, 51-56.	0.5	3
272	Decrease of calbindinâ€d28k, calretinin, and parvalbumin by taurine treatment does not induce a major susceptibility to kainic acid. Journal of Neuroscience Research, 2011, 89, 1043-1051.	2.9	3
273	p21WAF1/Cip1 is not involved in kainic acid-induced apoptosis in murine cerebellar granule cells. Brain Research, 2004, 1030, 297-302.	2.2	2
274	Tau hyperphosphorylation and axonal damage induced by N,Nâ€diethyldithiocarbamate (DEDTC) treatment along late postnatal development is followed by a rescue during adulthood. Journal of Neuroscience Research, 2010, 88, 1083-1093.	2.9	2
275	Editorial: Advances in the Treatment of Neurodegenerative Diseases and Epilepsy. Current Pharmaceutical Design, 2013, 19, 6699-6700.	1.9	2
276	Dual Mkk4 and Mkk7 Gene Deletion in Adult Mouse Causes an Impairment of Hippocampal Immature Granule Cells. International Journal of Molecular Sciences, 2021, 22, 9545.	4.1	2
277	Potential preventive disease-modifying pharmacological strategies to delay late onset Alzheimer's disease. Neural Regeneration Research, 2019, 14, 1721.	3.0	2
278	JNK1 and JNK3: divergent functions in hippocampal metabolic-cognitive function. Molecular Medicine, 2022, 28, 48.	4.4	2
279	Peroxisomal Proliferator-Activated Receptor $\hat{I}^2/\hat{I}^2$ Deficiency Induces Cognitive Alterations. Frontiers in Pharmacology, 0, 13, .	3.5	2
280	Role of cdk5 on ATM phosphorylation in neuronal death induced by DNA damage. Future Neurology, 2009, 4, 283-285.	0.5	1
281	Resveratrol: A Therapeutic Approach to Neurodegenerative Diseases and Aging. Mini-Reviews in Organic Chemistry, 2010, 7, 267-271.	1.3	1
282	JNK isoforms control mammal adult hippocampal neurogenesis. Mexican Journal of Medical Research ICSA, 2020, 8, 5-12.	0.2	1
283	GSPE pre-treatment protects against long-term cafeteria diet-induced mitochondrial and inflammatory affectations in the hippocampus of rats. Nutritional Neuroscience, 2022, 25, 2627-2637.	3.1	1
284	Dexibuprofen loaded PEGylated nanospheres for Alzheimer's disease treatment. Journal of Controlled Release, 2017, 259, e29-e30.	9.9	0
285	New Targets and Strategies of Medical Treatments in Neurological and Neurodegenerative Disorders. Current Pharmaceutical Design, 2020, 26, 1233-1234.	1.9	0
286	Pharmacological drug strategies in Alzheimer's Disease. Revista Neurociencias, 0, 29, .	0.0	0
287	Sirtuin and Resveratrol. Oxidative Stress and Disease, 2009, , .	0.3	0
288	Cell Cycle Control by Ataxia Telangiectasia Mutated Protein Through Regulating Retinoblastoma Protein Phosphorylation. , 2012, , 103-115.		0

#	Article	IF	CITATIONS
289	Peripheral and central effects of dexibuprofen on APP/PS1 mice fed with an obesogenic diet. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-1-16.	0.0	0
290	EPIGALLOGATECHIN-3-GALLATE IMPROVES COGNITIVE DECLINE AND METABOLIC ALTERATIONS IN APP/PS1 FAMILIAL MODEL OF ALZHEIMER'S DISEASE FED WITH HIGH FAT DIET. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO1-1-32.	0.0	0
291	Design of nanoparticles functionalized with cell penetrating peptides for the treatment of Alzheimer's disease. , 0, , .		0
292	Therapeutic Strategies for Neurological Disorders: From Natural Compounds to Innovative Molecular Designs. Current Pharmaceutical Design, 2022, 28, i-ii.	1.9	0